Merus N.V.
↗Utrecht, Netherlands
Merus is a clinical-stage oncology company developing innovative multispecific antibody therapeutics. Their proprietary Biclonics® and Triclonics® platforms allow for the rapid discovery and development of full-length human bispecific and trispecific antibodies that target multiple pathways simultaneously to treat cancer.
The company's approach focuses on 'Multispecifics' that can bind to different targets or different epitopes on the same target, aiming to overcome resistance mechanisms and improve efficacy compared to conventional monoclonal antibodies. Merus has established significant collaborations with major pharmaceutical companies to leverage its platform for a wide range of oncology indications.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$30M-$60M (Collaboration revenue)
Founded:2003
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$500M+
Investors:Bay City Capital, LSP (Life Sciences Partners), Johnson & Johnson Innovation, Pfizer Venture Investments, Novartis Venture Fund
STOCK
Exchange:NASDAQ
Ticker:MRUS
Market Cap:$3.2B
PIPELINE
Stage:Commercial (BLA Stage)
Lead Drug Stage:BLA Submitted / Priority Review
Modalities:Bispecific Antibodies (Biclonics®), Trispecific Antibodies (Triclonics®), mAbs
Active Trials:12
Trial Phases:Phase 1: 4 | Phase 2: 6 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Merus US, Inc.
Key Partnerships:Gilead Sciences (Trispecific collaboration), Loxo Oncology at Eli Lilly (CD3 T-cell engagers), Incyte Corporation (Bispecific discovery), Betta Pharmaceuticals (China rights for MCLA-129)
COMPETITION
Position:Leader
Competitors:Genmab, Zymeworks, Amgen, Macrogenics, Roche (Bispecific programs)
LEADERSHIP
Key Executives:
Bill Lundberg, M.D. - President and CEO
Hui Liu, Ph.D. - Chief Business Officer
Scientific Founders:Ton Logtenberg, Ph.D.
Board Members:Mark Iwicki, Anand Mehra, Victor Sandor
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Merus N.V. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Merus N.V.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.